Humacyte, Inc. (HUMAW)
Humacyte, Inc. (HUMAW)
| Cash Flow | 2026-03-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|
| Net (loss) income | -1,590 | -17,510 | 1,481 |
| Depreciation expense | -2,645 | 1,342 | 2,645 |
| Stock-based compensation expense | -4,113 | 2,461 | 4,822 |
| Change in fair value of contingent earnout liability | 44,422 | -4,893 | -44,261 |
| Non-cash interest expense | -6,446 | 2,288 | 4,367 |
| Change in fair value of derivatives | -9,666 | 4,009 | 14,182 |
| Inventory reserve | 1,626 | NaN | NaN |
| Amortization expense | -1,122 | 523 | 1,047 |
| Non-cash operating lease costs | -44 | 15 | 29 |
| Amortization of debt discount | 282 | NaN | NaN |
| Accounts receivable | -905 | 684 | 214 |
| Inventory | -20,313 | 7,302 | 10,968 |
| Prepaid expenses and other current assets | 1,878 | 64 | -505 |
| Accounts payable | -5,496 | 2,987 | 2,147 |
| Accrued expenses | -738 | 957 | -2,403 |
| Finance lease obligation | -628 | NaN | NaN |
| Revenue interest payments | NaN | 45 | NaN |
| Operating lease obligation | 44 | -15 | -29 |
| Partial call payment under amended revenue interest purchase agreement | NaN | 50,000 | NaN |
| Net cash used in operating activities | 53,814 | -23,904 | -55,014 |
| Proceeds from revenue interest purchase agreement | NaN | 0 | 0 |
| Purchase of property and equipment | -670 | 49 | 796 |
| Proceeds from jdrf agreement | NaN | 0 | 0 |
| Net cash used in investing activities | 670 | -49 | -796 |
| Payments of costs related to public offering-ATMFacility | NaN | NaN | 100 |
| Proceeds from the issuance of common stock-Public Stock Offering | -47,000 | 0 | 47,000 |
| Payments of costs related to public offering | NaN | 0 | 340 |
| Proceeds from the issuance of common stock-Registered Direct Offerings | 18,676 | NaN | NaN |
| Proceeds from the issuance of common stock-ATMFacility | -5,155 | 6,197 | 3,603 |
| Proceeds from the issuance of common stock-Equity Line Financing | NaN | 0 | NaN |
| Proceeds from the exercise of stock options | -56 | 0 | 56 |
| Payments of finance lease principal | -2,157 | 743 | 1,414 |
| Payments of transaction costs related to revenue interest purchase agreement | NaN | 0 | 0 |
| Net cash provided by financing activities | 19,007 | -44,591 | 48,905 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 73,491 | -68,544 | -6,905 |
| Cash, cash equivalents and restricted cash at the beginning of the period | 19,841 | 95,290 | NaN |
| Cash, cash equivalents and restricted cash at the end of the period | 48,892 | 19,841 | NaN |